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Although the herpes simplex virus thymidine kinase gene has
been frequently applied as a reporter gene for monitoring gene
transfection in animals, it has some intrinsic limitations for use in
humans. In our search for a reporter gene that lacks these
limitations, we have evaluated the feasibility of the human nor-
epinephrine transporter (hNET) as a reporter gene in combina-
tion with the reporter probe 11C-m-hydroxyephedrine (mHED)
for PET. Methods: An adenoviral vector (AdTrack-hNET) con-
taining the hNET gene as reporter gene and the enhanced green
fluorescent protein (EGFP) as a substitute for a therapeutic gene
was constructed. After COS-7, A2780, and U373 cells were
transiently transduced with AdTrack-hNET, hNET protein ex-
pression, EGFP fluorescence, and cellular uptake of 11C-mHED
were determined. In rats, U373 tumor xenografts were grown
and transiently transduced with either AdTrack-hNET or an
AdTrack-Luc control adenovirus. Intratumoral accumulation of
11C-mHED was determined by PET and ex vivo biodistribution.
The tumors were subsequently examined for EGFP fluores-
cence. Results: 11C-mHED uptake was positively correlated
with AdTrack-hNET viral titer and hNET protein expression.
However, large differences in transfection efficiency between
cell lines were observed. The highest 11C-mHED uptake was
found in hNET transfected U373 cells, in which tracer uptake
was 70-fold higher than that in control cells. 11C-mHED accu-
mulation could be inhibited by desipramine, a potent inhibitor of
hNET. In all cell lines, 11C-mHED uptake was positively corre-
lated with EGFP fluorescence, implying that imaging of hNET
with 11C-mHED would enable monitoring of a coexpressed ther-
apeutic gene. In the animal model, gene transfection efficiencies
were very low, as determined by EGFP fluorescence. Still, a
significantly higher 11C-mHED uptake in hNET transduced tu-
mors than that in control tumors was demonstrated by ex vivo
biodistribution studies. PET with a clinical camera could visual-
ize 1 of 3 hNET transduced tumors, indicating that the trans-
fection efficiency was near the detection limit. Conclusion:
These results indicate that monitoring of gene therapy using the
hNET/11C-mHED reporter gene/probe is feasible, but further
investigation with regard to the sensitivity of the technique is
required.
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Several clinical protocols for gene therapy are being
evaluated as treatment for human disease. However, thus
far, gene therapy has not come up to the expectations, as
difficulties to accomplish controlled, selective, and effective
delivery of genes to target cells have limited its success. To
evaluate and improve gene delivery strategies, measurement
of therapeutic gene expression is of major importance. For
some therapeutic genes, direct imaging of the gene of in-
terest is possible, but for the majority of therapeutic genes,
no radiotracers are available for imaging. In these cases, a
reporter gene can be coupled to the therapeutic gene of
interest. In this way, the expression of the therapeutic gene
can be monitored indirectly via imaging of the linked re-
porter gene with a suitable reporter probe (1,2). In principle,
the expression of any therapeutic gene can be evaluated by
this indirect imaging approach.
The herpes simplex virus thymidine kinase (HSVtk) gene
has been studied most extensively as a reporter gene for
gene therapy. Several thymidine- and acycloguanosine-de-
rived tracers have been investigated as reporter probes for
imaging of HSVtk (2). The 124I-labeled thymidine-derived
tracer 5-124I-iodo-2-fluoro-2-deoxy-1--D-arabinofurano-
syl-5-iodouracil (124I-FIAU) and the 18F-labeled acy-
cloguanosine derivative 9-(4-18F-fluoro-3-hydroxymethyl-
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butyl)guanine (18F-FHBG) have already been studied in
humans (3,4). The advantage of an enzyme-based reporter
gene such as HSVtk is that the gene product can induce
signal amplification. An important limitation of HSVtk as a
reporter gene is the fact that it is a foreign gene and could
therefore provoke an immune response. Another disadvan-
tage of an intracellularly expressed enzyme such as HSVtk
is that the transport of the reporter probe into the cell can be
rate limiting (5–7).
Other reporter genes that have been previously studied
include the human dopamine D2 receptor (D2R) gene, the
human somatostatin receptor subtype 2 (hSSTr2), and the
sodium iodide symporter (NIS) gene (8). The advantage of
the receptor-based systems is that the genes are expressed
on the cell surface and, therefore, can be reached easily by
the reporter probes. Furthermore, the D2R and hSSTr2 are
encoded by endogenous genes and, therefore, do not elicit
an immune response. However, this characteristic can also
lead to high background levels due to reporter probe accu-
mulation in host tissues. Furthermore, the receptor-based
systems do not have the advantage of signal amplification:
In general, only one reporter probe molecule can be retained
per receptor molecule. In the case of low gene transfer, the
produced reporter probe signal may not be high enough for
imaging of the reporter gene.
The NIS can be visualized with radioactive iodide by
SPECT and PET (9). Although the NIS can induce signal
amplification, rapid release of radioactive iodide from NIS
transfected cells has also been observed (10). Consequently,
cells that are transfected with the NIS gene do not always
sufficiently retain the radiotracer (11).
Thus, the currently available reporter genes for imaging of
gene therapy have not only their specific advantages but also
their own intrinsic disadvantages. Therefore, other reporter
genes for imaging of gene therapy in humans are still required.
We investigated the potential of the human norepineph-
rine transporter (hNET) gene as reporter gene and 11C-m-
hydroxyephedrine (mHED) as reporter probe for imaging of
gene therapy. hNET is a transmembrane protein that is
found at noradrenergic nerve terminals and mediates the
active reuptake of norepinephrine that is released by neu-
rons. The norepinephrine is subsequently stored in neuronal
vesicles by the vesicular monoamine transporter (12–14).
The expression of hNET is almost completely restricted to
structures of the sympathetic nervous system (heart, brain).
This allows the imaging of hNET as a reporter gene in all
organs without sympathetic innervation. Other advantages
of the hNET gene as reporter gene is that hNET is expressed
in the cell membrane, so limited membrane transport of the
reporter probe will not be a problem. 11C-mHED is a good
substrate for the hNET (uptake-1) carrier and several tracer
molecules can be transported by a single carrier protein
molecule, thus resulting in signal amplification. Further-
more, hNET is an endogenous protein and, as a conse-
quence, the reporter gene product will not induce an immu-
nologic reaction. The small size (2 kb) of the hNET gene
allows it to be easily incorporated in the expression cassette
of the delivery vehicle when the hNET gene is linked to the
therapeutic gene.
11C-mHED is structurally closely related to norepineph-
rine (Fig. 1A) and has been applied as a PET tracer for
assessment of the integrity of presynaptic sympathetic nerve
terminals (15). 11C-mHED has demonstrated highly specific
uptake and retention in sympathetic nerve terminals of the
heart. The radiotracer shares the same neuronal uptake
mechanism as norepinephrine, but it is resistant to metabo-
lism by monoamine oxidase and catechol-O-methyltrans-
ferase (16,17). Retention of 11C-mHED in hNET-expressing
tissue is the result of rapid hNET-mediated reuptake of the
tracer. 11C-mHED is rapidly cleared from plasma and whole
blood. There is a rapid excretion of 11C-mHED from kidney
to the urinary tract (18). 11C-mHED is relatively polar and,
therefore, nonspecific uptake is low. High target-to-back-
ground ratios can be obtained early after injection of 11C-
mHED (19). The use of hNET as a reporter gene has been
studied previously using radiolabeled metaiodobenzylgua-
nine (MIBG) as the reporter probe. For PET, MIBG can be
labeled with 124I. However, the clinical usefulness of 124I is
rather limited. The synthesis of MIBG analogs, labeled with
the PET nuclide 18F, has also been described; however,
these tracers have not yet been applied in humans. 11C-
mHED on the other hand, is a well-established PET tracer
and has already been safely applied in humans.
In this study, the feasibility of hNET as a reporter gene
for monitoring therapeutic gene expression was investi-
gated. To this end, cells were transduced with an adenoviral
vector containing both hNET as the reporter gene and the
enhanced green fluorescent protein (EGFP) as a substitute
for a therapeutic gene. Both in vitro and in vivo, the uptake
of 11C-mHED in hNET transduced cells was studied and the
correlations with hNET expression and EGFP fluorescence
were examined.
FIGURE 1. (A) Chemical structures of norepinephrine (left)
and 11C-mHED (right). (B) Genome of the first-generation ade-
noviral vector, containing transgenes EGFP (enhanced green
fluorescence protein) and hNET, located in region of the E1
deletion. The 2 transgenes are expressed from identical but
separate expression cassettes. CMVp  cytomegalovirus pro-
moter; ITR  inverted terminal repeat.
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MATERIALS AND METHODS
Materials
RPMI 1640 medium, trypsin (2.5%, w/v), restriction enzymes,
and Lipofectamine PLUS reagent were purchased from Invitrogen.
Fetal calf serum (FCS) and Matrigel were obtained from PAA
Laboratories. Dulbecco’s minimum essential medium (DMEM),
penicillin, and streptomycin were purchased from GibcoBRL, Life
Technologies BV. The pcDNA3-hNET plasmid was a generous
gift from Randy D. Blakely (20). The pcDNA3.1()mychisLacZ
plasmid was acquired from Invitrogen. The hNET antibody
(NET17-1) was purchased from MAB Technologies Inc. The
rabbit anti-mouse IgG antibody, chemically conjugated to horse-
radish peroxidase, was purchased from DakoCytomation BV. Met-
araminol bitartrate salt was obtained from Sigma.
Cell Lines
The green monkey kidney cell line COS-7, the human glioma
cell line U373, and the human kidney cell line HEK293 were
obtained from the American Type Culture Collection. The human
ovarian carcinoma cell line A2780 was obtained from Dr. Robert
Ozols (Philadelphia, PA). COS-7 cells were cultured in DMEM
supplemented with 5% FCS, 50 IU/mL penicillin, and 50 g/mL
streptomycin. U373 and HEK293 cells were cultured in DMEM/
F12 medium supplemented with 10% FCS, 50 IU/mL penicillin,
and 50 g/mL streptomycin. A2780 cells were cultured in RPMI
1640 medium supplemented with 10% FCS. All cells were cul-
tured in a humidified atmosphere with 5% CO2 at 37°C.
Construction of Adenoviral Vector
First-generation (both E1 and E3 regions are deleted from the
viral genome) adenoviral vectors were constructed using the Ad-
Easy system (21). The adenovirus (AdTrack-hNET) contains the 2
transgenes EGFP and hNET, which are expressed from identical
but separate expression cassettes (Fig. 1B). The control virus
(AdTrack-Luc) contains EGFP and luciferase (Luc). Both viruses
are based on the shuttle plasmid pAdTrack-CMV. The hNET gene
was inserted as XhoI–XbaI fragment of the plasmid pcDNA3-
hNET into the corresponding sites in pAdTrack-CMV. The result-
ing shuttle plasmid was recombined with the plasmid pAdEasy-1
containing part of the adenoviral genome to form viral DNA,
which was subsequently transfected into HEK293 cells to produce
viral particles. Virus was purified by CsCl gradient.
Preparation of 11C-mHED
Metaraminol bitartrate salt (Sigma; 3 mg) was dissolved in 38
L of 0.5N NaHCO3. At 125°C, the product was azeotropically
dried with 2  1 mL of acetonitrile using an argon flow. The
residue was resuspended in 0.3 mL of acetonitrile and the clear
supernatant containing the metaraminol (free base) was transferred
into a clean dry minivial.
11C-Methane was produced by the 14N(p,	)11C nuclear reaction,
using a Scanditronix MC17 cyclotron to irradiate the N2 
 5% H2
target gas with 17-MeV protons. 11C-Methyl iodide was prepared
from 11C-methane (22) and converted into 11C-methyl triflate (23)
by previously described procedures. 11C-Methyl triflate was trans-
ported by a stream of argon (20 mL/min) into the minivial con-
taining the metaraminol solution. After the trapping of 11C-methyl
triflate was complete, the solvent was evaporated at 125°C with the
aid of an argon flow. The residue was dissolved in 1 mL of water
and purified by semipreparative reversed-phase high-performance
liquid chromatography (HPLC) using a Bondapak C18 column
(Waters-Millipore; 10 m, 300  7.8 mm) and 1% ethanol in 0.01
mol/L H3PO4 as the eluent at a flow of 3 mL/min. The radioactive
product with a retention time of 8 min was collected (retention
time of metaraminol, 5 min) and neutralized with 0.5N NaOH. In
this manner, 11C-mHED with a specific activity of 11  6 GBq/
mol was prepared in 65%  14% decay-corrected radiochemical
yield (based on 11C-methyl triflate). The identity of the product
was confirmed by coinjection with a reference sample on reversed-
phase HPLC.
Accumulation of 11C-mHED in hNET Transfected Cells
Cells were seeded in 12-well plates at a density so that cells
were 70% confluent the next day. Two days after seeding, the cells
were infected with adenovirus at various multiplicities of infection
(MOI) by adding AdTrack-hNET virus to the cells in fresh culture
medium (MOI 30, 100, 300, and 1,000 for COS-7 cells and A2780
cells and MOI 0, 30, 50, 70, 100, and 300 for U373 cells). Control
cells were infected with AdTrack-Luc. After 2 h of infection, the
medium was changed to fresh medium without virus. Two days
after infection, the cells were incubated with 44  15 MBq of
11C-mHED for 1 h. For competition experiments, desipramine
(DMI) was added 5 min before the tracer (final DMI concentration,
6 mol/L). After tracer incubation, the culture medium was re-
moved and the monolayers were washed 3 times with 1.0 mL of
phosphate-buffered saline (PBS). The cells were harvested from
the culture plates by treatment with 0.25 mL of trypsin. The cells
were resuspended in 1.2 mL of culture medium to neutralize the
trypsin. A 50-L sample was taken and mixed with 50 L of
trypan blue to count the number of viable cells under a microscope.
The radioactivity in the cell suspensions was measured in a
-counter (LKB, Wallac) and normalized to the number of viable
cells. Results are reported as the percentage of tracer dose per
million cells (%ID/106 cells). For COS-7 cells, 3 independent
experiments were performed, either in duplicate or triplicate. For
A2780 cells, 1 experiment was performed in duplicate. Two ex-
periments (each in quadruplicate) were performed for U373 cells.
hNET Protein Expression
hNET protein expression was determined in cells grown and
infected parallel to the cells used for 11C-mHED accumulation
experiments. EGFP expression of cells for the protein isolation
was comparable to the cells used for the accumulation experi-
ments. Cells were detached by scraping the cells in 500 L of PBS
and lysed by adding 2.5 L of 20% (w/v) sodium dodecyl sulfate.
Lysates were analyzed by dot blot and immunohistochemistry.
Protein was detected with NET17-1, a mouse antibody directed
against the extracellular domain of the hNET protein, and a rabbit
secondary antibody linked to horseradish peroxidase. Blots were
stained using enhanced chemoluminescence ([ECL] ECL plus
Western Blotting Detection system (Amersham Biosciences, Ltd.).
The amount of protein was quantified on the western blot using the
Quantity One program (Bio-Rad Laboratories) and expressed in
arbitrary units. The method was validated by determining the
correlation between ECL intensity and the amount of protein and
the detection range using increasing amounts of an unrelated
protein.
EGFP Analysis
EGFP expression in the transfected cells was measured imme-
diately before the start of the 11C-mHED accumulation experi-
ments by measuring the EGFP intensity in an FL500 microplate
fluorescence reader (Bio-Tek Instruments; excitation, 485 nm;
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emission, 508 nm). The EGFP intensity was expressed in arbitrary
units.
Animal Model
U373 cells (2  107 cells in 0.2 mL of culture medium) were
mixed 1:1 with Matrigel and injected subcutaneously into the left
and right shoulder of male nude rats (HSD RH rnu, Harlan; body
weight, 140–200 g). When solid tumor nodules had grown to
approximately 1.0 cm in diameter (after approximately 2 wk), they
were injected with AdTrack-hNET adenovirus (1010 plaque-form-
ing units; 5.7  1010 viral particles in 80 L) in 1 tumor and with
AdTrack-Luc control virus (5.7  1010 viral particles in 80 L) in
the contralateral tumor by single injection of the adenoviruses. All
studies were performed in compliance with the national law and
the local ethical guidelines for animal experiments. The protocols
were approved by the Animal Ethics Committee of the Groningen
University.
In Vivo Accumulation of 11C-mHED
PET studies were performed using a Siemens Exact HR

positron camera (Siemens/CTI) with a resolution of about 5 mm
(full width at half maximum). Transmission and emission scans
were obtained in 2-dimensional mode. Two days after virus deliv-
ery, the rats (n  3) were anesthetized with an intraperitoneal
injection of a mixture of ketamine (25 mg/kg) and medetomidine
(1 mg/kg). The animals were positioned in the PET camera with
their long-axis parallel to the transaxial plane of the tomograph. A
transmission scan was obtained to correct for attenuation of 511-
keV photons by tissue. Subsequently, 42  6 MBq of 11C-mHED
was injected into the tail vein and data acquisition was started.
Data were acquired for 1 h using the following frames: 6 consec-
utive frames of 10 s, 2 of 30 s, 3 of 60 s, 2 of 120 s, 2 of 180 s,
3 of 300 s, and 3 of 600 s. Emission scans were corrected for
radioactive decay, attenuation, random counts, and dead time.
After the PET scan was completed, the rats were sacrificed by
extirpation of the heart. Tumors were dissected and weighed and
the accumulated radioactivity was measured with a -counter.
Tracer accumulation is expressed as percentage of injected dose
per gram tissue (%ID/g). EGFP expression in tumor was visualized
under a fluorescence microscope in cryosections. Series of 4-m
sections from 4 randomly chosen sites were prepared from each
tumor. The sections were placed on a glass slide and examined
unfixed and unstained.
Statistical Analysis
Differences in tracer accumulation were analyzed using a
2-sided unpaired Student t test for in vitro studies and a 2-sided
paired Student t test for in vivo experiments. P  0.05 was
considered significant.
RESULTS
Accumulation of 11C-mHED in hNET Transfected Cells
11C-mHED uptake was determined in COS-7 cells that
were infected with AdTrack-hNET virus at various MOIs
(MOI 30, 100, 300, and 1,000) and with AdTrack-Luc
control virus (MOI 100). Figure 2 shows that the uptake of
the tracer in the AdTrack-hNET transfected cells increased
with increasing viral titers. After 1 h of incubation with
11C-mHED, the tracer uptake in hNET transfected cells at
the highest viral titer (MOI 1,000: 14.6  2.8 %ID/106
cells) was approximately 17-fold higher than that in cells
transfected with control virus. Incubation with 11C-mHED
in the presence of DMI (a potent antagonist of norepineph-
rine transport) reduced tracer uptake in hNET transfected
cells to the level of control cells (cells infected with control
virus; Fig. 2). The DMI-induced reduction in tracer uptake
was statistically significant for cells infected with AdTrack-
hNET at MOI 100 or higher (P  0.01).
Over the range of viral titers used, 11C-mHED uptake
showed an excellent linear correlation with the viral titer not
only for COS-7 cells (r2  0.997; P  0.0002) but also for
A2780 cells (r2  0.949; P 0.02) and for U373 cells (r2 
0.994; P  0.0001). However, the slope of the plot of the
tracer uptake versus the viral titer was strongly dependent
on the type of cell line used (Fig. 3). At the highest viral
titer, 11C-mHED uptake in hNET transfected A2780 cells
(MOI 1,000: 4.4  0.8 %ID/106 cells) was approximately
3.5-fold lower than that in transfected COS-7 cells. The
11C-mHED uptake in transfected U373 cells, on the other
hand, was approximately 11-fold higher than tracer uptake
in transfected COS-7 cells. The tracer uptake in U373 cells
transfected with the highest viral AdTrack-hNET titer (MOI
300: 47  25 %ID/106 cells) was 70-fold higher than that
in control cells.
hNET Protein Expression
The amount of hNET protein was determined in U373
cells. Figure 4 shows a good correlation between the amount
of hNET protein and the 11C-mHED uptake (r2  0.987;
P  0.0001). This indicates that the transduced hNET gene
produces functional hNET protein and that 11C-mHED up-
take correctly reflects the magnitude of hNET expression.
FIGURE 2. 11C-mHED uptake in COS-7 cells transfected with
adenoviral AdTrack-hNET at various MOI. MOI  0 represents
control (cells infected with AdTrack-Luc). Two days after trans-
fection, cells were assayed for 11C-mHED accumulation in pres-
ence or absence of 6 mol/L DMI. Three independent experi-
ments were performed, either in duplicate or triplicate.
Average SD is shown. *Significantly higher uptake than that of
DMI-treated cells (P  0.05).
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EGFP Analysis
In COS-7, A2780, and U373 cells, EGFP fluorescence
was measured in the cells just before addition of the tracer.
The tracer uptake versus EGFP fluorescence is shown in
Figure 5. EGFP fluorescence shows a good linear relation-
ship with 11C-mHED uptake in the 3 cell lines tested (r2 
0.965, P  0.003 for COS-7 cells; r2  0.989, P  0.0005
for A2780 cells; r2  0.979, P  0.0002 for U373 cells),
indicating that EGFP expression was positively correlated
with hNET expression.
Accumulation of 11C-mHED In Vivo
To investigate the transfection with the hNET gene in
vivo, 11C-mHED uptake was studied in rats bearing 2 sub-
cutaneous U373 tumor xenografts that were injected with
either AdTrack-hNET adenovirus or AdTrack-Luc control
FIGURE 3. 11C-mHED uptake vs. viral titer in COS-7 cells,
A2780 cells, and U373 cells. Cells were transduced with
AdTrack-hNET at various MOI. MOI 0 represents control (cells
infected with AdTrack-Luc). Two days after infection, cells were
assayed for 11C-mHED accumulation. In all cell lines, 11C-mHED
uptake increased linearly with viral titer (r2  0.997 for COS-7
cells, r2  0.949 for A2780 cells, and r2  0.994 for U373 cells;
P  0.05). Error bars represent SD.
FIGURE 4. 11C-mHED uptake vs. amount of hNET protein in
U373 cells. hNET protein expression was determined in U373
cells grown and transfected parallel to cells used for 11C-mHED
accumulation experiments 2 d after infection. Good correlation
between amount of hNET protein and 11C-mHED uptake is
evident (r2  0.987; P  0.0001). Error bars represent SD.
FIGURE 5. 11C-mHED uptake vs. EGFP fluorescence in
COS-7 cells (A), A2780 cells (B), and U373 cells (C). Cells were
transduced with AdTrack-hNET. Two days after infection, EGFP
intensity was measured immediately before the start of 11C-
mHED accumulation experiments. In all 3 cell lines, EGFP fluo-
rescence correlated well with 11C-mHED uptake (r2  0.965 for
COS-7 cells, r2 0.989 for A2780 cells, and r2 0.979 for U373
cells; P  0.005). Error bars represent SD.
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virus 2 d before PET. 11C-mHED PET images showed high
tracer uptake in heart, liver, kidney, and bladder. The hNET
transfected tumor was visible in 1 of 3 animals at 1 h after
injection of the tracer, whereas the control tumor could not
be discerned in any of the animals (Fig. 6).
After PET, tumors were excised and 11C-mHED uptake
was determined by ex vivo -counting. In all animals, tracer
accumulation was consistently 14%–27% higher in hNET
transfected tumors than that in control tumors. As a result,
average 11C-mHED uptake in the hNET transfected tumors
(0.13  0.02 %ID/g) was significantly higher (paired t test,
P  0.05) than 11C-mHED uptake in tumors transfected
with control virus (0.11  0.01 %ID/g).
To determine the extent of transgene expression, random
tumor sections were cut and EGFP expression was investi-
gated by fluorescence microscopy. EGFP fluorescence
could be visualized in only 2 of 24 series of tumor sections.
In both sections, a clear patch of fluorescent cells of ap-
proximately 1 mm in diameter could be seen (Fig. 7). These
results indicate that only a small fraction of the tumor cells
was transfected and expressed the transgene.
DISCUSSION
Monitoring the efficiency and spatial distribution of
transduction of a therapeutic gene is highly desirable for the
development of safe and efficient gene therapy for treatment
of human disease. In our search for a reporter system with
optimal characteristics, we investigated the feasibility of
hNET as a reporter gene for imaging of gene therapy. The
use of hNET as a reporter gene has been studied previously
using radiolabeled MIBG as the reporter probe (24). Radio-
labeled MIBG is a promising radiopharmaceutical for tar-
geted radiotherapy. Tumors derived from the neural crest
(neuroblastoma and phaeochromocytoma) respond to 131I-
MIBG–mediated radiotherapy by actively taking up 131I-
MIBG via the hNET (25,26). It has been demonstrated that
131I-MIBG can also be used as a radiotherapeutic agent in
tumors other than those derived from the neural crest. Tu-
mor cells, which do not express hNET, can be transfected
with the hNET gene, which results in an enhanced 131I-
MIBG uptake and related toxicity (27–30).
PET seems to be the method of choice for monitoring
gene transduction because of its high sensitivity and its
ability to generate quantitative results. However, for imag-
ing reporter gene expression with PET, MIBG is not the
most suitable tracer. The PET isotope 124I has a relatively
long half-life (4.2 d) and emits high-energy -rays, and only
23% of the disintegrations produce positrons. These char-
acteristics reduce the quality of the PET images, complicate
quantification, and could limit the dose administered to
patients, which makes the clinical usefulness of 124I rather
limited (31,32). MIBG analogs, labeled with the more con-
ventional PET nuclide 18F, have also been synthesized;
however, none of them is used in clinical practice (33).
Therefore, we have chosen to evaluate 11C-mHED as the
reporter probe for PET of the reporter gene hNET. 11C-
mHED is a polar compound with low nonspecific uptake.
Because of its rapid accumulation in target tissue and fast
clearance from plasma, high-contrast 11C-mHED PET im-
ages can be obtained soon after injection of the tracer (34).
Together with the short half-life of 11C (20 min), this would
allow rapid repetitive imaging. On the other hand, the short
half-life may be a potential limitation as the accumulation of
the tracer in the tumor may be expected to rise over time
while the background signal would wash out, leading to an
increased signal-to-background ratio at later time points.
FIGURE 6. Anterior 11C-mHED PET image of HSD RH rnu rat
bearing 2 U373 tumors that were either transfected with adeno-
viral vector AdTrack-hNET (top) or control vector (bottom) 2 d
before PET study. PET image was obtained 50–60 min after
injection of 42  6 MBq of 11C-mHED tracer. Image is summa-
tion of all coronal planes, on which animal was visible.
FIGURE 7. Visualization of EGFP fluo-
rescence in tumor tissue. EGFP expression
in tumor tissue was visualized under fluo-
rescence microscope in 4-m cryosec-
tions. (A) Phase-contrast image. (B) EGFP
fluorescence. (C) Merged picture.
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In the above studies, in which MIBG was used as the
reporter probe to image hNET transgene expression, stably
transduced cell lines and tumors were used. This approach
ensures that the percentage of transfected cells is high and,
consequently, high levels of tracer uptake can be achieved.
In clinical practice, however, transfection efficiencies are
usually low.
To mimic the clinical situation more closely in this study,
we used tumor cells and tumor xenografts that were tran-
siently transfected with an adenoviral construct. In cell
experiments, we have shown that hNET can be successfully
transfected into various cell lines using the AdTrack-hNET
adenoviral vector. Transfected cells produced functional
hNET protein. Cellular 11C-mHED uptake correlated well
with the expression of the hNET reporter gene. When the
hNET transporter was inhibited with DMI, the cellular
11C-mHED uptake was reduced to the level of control cells.
These results indicate that cellular 11C-mHED uptake is
specific for hNET and, thus, is a suitable measure for the
reporter gene expression after gene transduction.
In all cell lines tested, 11C-mHED increased linearly with
increasing viral titer. However, at an established viral titer,
the 11C-mHED uptake varied to a great extent between the
different cell lines. Apparently, the different cell types
showed variable degrees of susceptibility to adenoviral in-
fection, resulting in variable levels of expression of the
hNET gene. Adenoviral infection is mediated by the cox-
sackie adenovirus receptor (CAR). The differences in infec-
tion susceptibility between cell lines is probably caused by
differences in expression levels of the CARs. It has been
shown that a deficiency of the primary receptor for adeno-
viruses on tumor cells limits the efficiency of adenovirus-
mediated gene transfer in vivo (35). A2780 cells have low
expression levels of the CAR (36), which would explain the
low transfection efficiency and low cellular 11C-mHED up-
take that was observed in this cell line.
To test the feasibility of hNET as a reporter gene, we
have used an adenoviral vector, which contains both the
hNET reporter gene and the EGFP gene, under control of
the same promoter. In this way, we hypothesized equal
expression of both genes. In all cell lines, EGFP fluores-
cence was positively correlated with the 11C-mHED uptake,
indicating a linear relationship between EGFP expression
and hNET expression. Thus, the hNET/11C-mHED appears
to be a suitable reporter gene/probe system to monitor the
expression of a second gene in the transfection vector. This
approach should be easily adaptable to clinical protocols by
replacing the EGFP with any therapeutic gene of choice.
Thus, imaging of hNET with 11C-mHED could enable mon-
itoring of a coexpressed therapeutic gene.
To test the feasibility of the reporter system in vivo, the
adenoviral vector was injected in U373 tumors grown in
rats. In contrast to the in vitro results, in vivo gene trans-
fection efficiency in the tumor was poor. Minor tumor
transfection was only observed in the immediate area of the
needle tract. Still, ex vivo biodistribution studies revealed a
consistent and significant elevation of 11C-mHED uptake
(19%  7%) in the AdTrack-hNET transfected tumors as
compared with the contralateral tumors that were trans-
fected with control virus. This increase in 11C-mHED up-
take may appear small compared with the in vitro data, but
it should be noted that transfection in the tumor was re-
stricted to only a small area of 1 mm in diameter around the
injection site. However, in the ex vivo biodistribution stud-
ies, the tracer uptake in the whole tumors (0.44  0.10 g)
was measured. From these data, it is estimated that 1% of
the cells in the tumor was transfected by the viral vector.
Obviously, the 11C-mHED uptake in the whole tumor
strongly underestimates the actual tracer uptake in the in-
fected region.
Despite the low in vivo transfection efficiencies, the
hNET transfected tumor could still be visualized by our
clinical PET camera in 1 of 3 animals. This indicates that
the transfection levels that were achieved in this study were
near the detection limit. Obviously, the detection limit was
strongly affected by partial-volume effects, as the spatial
resolution of the camera was about 4–5 mm, whereas the
transfected tumor area was only approximately 1 mm in
diameter. As a consequence, the hNET-derived signal was
averaged out over the resolution volume. Because a small-
animal PET camera is not available at our institution yet, we
performed our experiments with a clinical PET camera.
However, animal studies using a dedicated animal PET
camera with a resolution of 2 mm or human studies could
give a better indication of the sensitivity of 11C-mHED PET
for monitoring of hNET reporter gene expression.
CONCLUSION
hNET in combination with 11C-mHED appears to be a
promising reporter system for monitoring of gene therapy
with PET and should be applicable in clinical protocols. The
sensitivity of the technique, however, might be a limitation,
as the low transfection efficiencies that were achieved in
this study were near the detection limit. Therefore, further
studies are required to investigate whether 11C-mHED PET
is sensitive enough to detect clinically relevant levels of the
reporter gene after in vivo gene transfection.
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